News about "biotechnology company"

Cbio A/S Secures Regulatory Clearance for First-in-Human Trial of Novoleucel T-Cell Therapy for Cervical Cancer

Cbio A/S has received regulatory approval to begin a Phase I/IIa trial of novoleucel, a next-generation T-cell therapy, in patients with recurrent Cervical Cancer.

Biotechnology Company | 16/03/2026 | By News Bureau

Immunic Secures European Patent for Vidofludimus Calcium, Strengthening Long-Term Market Exclusivity

Immunic receives European patent protection for Vidofludimus Calcium dosing regimens, reinforcing intellectual property coverage and potentially extending exclusivity for the multiple sclerosis therapy in Europe until 2043.

Biotechnology Company | 12/03/2026 | By News Bureau

Antengene Licenses ATG-201 to UCB in Deal Worth Up to USD 1.1 Billion for Autoimmune Disease Therapy

Antengene grants UCB exclusive global rights to develop and commercialise ATG-201, a CD19/CD3 bispecific T-cell engager targeting autoimmune diseases, in a deal worth over USD 1.1 billion in milestones and royalties.

Biotechnology Company | 06/03/2026 | By News Bureau |  134

NOVOS Reports Positive Clinical Trial Results Showing Improvements in Vascular Aging Markers

A randomised clinical trial led by the University of Surrey found that NOVOS Core significantly improved endothelial function, arterial flexibility and systolic blood pressure in adults over 40 compared with placebo.

Biotechnology Company | 20/02/2026 | By News Bureau |  353

Sobi Completes Acquisition of Arthrosi Therapeutics to Strengthen Gout Pipeline with Phase III Asset Pozdeutinurad

Sobi has acquired Arthrosi Therapeutics, adding phase III gout candidate pozdeutinurad (AR882) to its portfolio, with trial results expected in 2026.

Biotechnology Company | 11/02/2026 | By News Bureau |  122

FDA Approves Tenpoint Therapeutics' Yuvezzi, First Dual-Action Eye Drop for Presbyopia

The US FDA has approved Yuvezzi (carbachol and brimonidine tartrate), the first dual-agent eye drop for presbyopia, offering significant near-vision improvement with favourable tolerability.

Biotechnology Company | 31/01/2026 | By News Bureau |  281

QureBio Reports Promising Phase Ib/II Data for Q-1802 in Advanced Gastric and GEJ Cancer

ASCO 2026 data show strong response rates and manageable safety for the bispecific antibody Q-1802 plus XELOX, supporting progression to a Phase III trial.

Biotechnology Company | 29/01/2026 | By News Bureau |  118

Olatec Therapeutics Presents Promising Preclinical Data for Dapansutrile in Parkinson's Disease at MJFF Forum

Olatec Therapeutics presented MJFF-funded preclinical data showing its oral NLRP3 inhibitor dapansutrile delivered disease-modifying effects across two translational Parkinson’s disease mouse models.

Biotechnology Company | 21/01/2026 | By News Bureau |  188

Insilico Medicine, Hygtia Therapeutics Partner to Co-Develop AI-Designed NLRP3 Inhibitor for CNS Disorders

Insilico Medicine and Hygtia Therapeutics have entered a co-development deal for ISM8969, an AI-designed, brain-penetrant NLRP3 inhibitor, with milestone payments of up to USD 66 million.

Biotechnology Company | 21/01/2026 | By News Bureau |  195

Brenig Therapeutics Initiates First-in-Human Study of BT-409, Advances BT-267 Parkinson's Programme

Brenig Therapeutics has launched a first-in-human Phase I study of BT-409, a brain-selective NLRP3 inhibitor, while advancing BT-267 toward Phase 1b and Phase II studies in Parkinson’s disease.

Biotechnology Company | 20/01/2026 | By News Bureau |  226